Immuno-oncology combinations: raising the tail of the survival curve
There have been exponential gains in immuno-oncology in recent times through the development of immune checkpoint inhibitors. Already approved by the U.S. Food and Drug Administration for advanced melanoma and non-small cell lung cancer, immune checkpoint inhibitors also appear to have significant a...
| Main Authors: | , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Chinese Anti-Cancer Association
2016
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4944548/ |